首页 › 乳腺癌 › 得克萨斯州 › Fort Worth
Fort Worth TX 乳腺癌临床试验
12项针对 乳腺癌的研究正在 Fort Worth及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study of PHST001 in Advanced Solid Tumors
招募中1 期
- START Center for Cancer Research - Texas, Fort Worth
IKS014 in Advanced Solid Tumors That Express HER2
招募中1 期
- START Dallas - Fort Worth, Fort Worth
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
招募中3 期
- JPS Health Network ( Site 0067), Fort Worth
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
招募中3 期
- The Center for Cancer and Blood Disorders ( Site 0041), Fort Worth
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
招募中3 期
- JPS Oncology and Infusion Center ( Site 0083), Fort Worth
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
招募中3 期
- JPS Health Network, Fort Worth
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
招募中3 期
- JPS Health Network - Trinity Springs Pavilion, Fort Worth
- OneR The Center For Cancer And Blood Disorders (Texas Cancer Care), Fort Worth
- UT Southwestern Moncrief Cancer Institute, Fort Worth
- 以及另外 2 项
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
招募中1 期
- Start - Dfw, Fort Worth
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
招募中3 期
- Research Site, Fort Worth
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
招募中3 期
- JPS Health Network, Fort Worth
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- USOR Texas Oncology, Fort Worth
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
招募中3 期
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
其他城市的 乳腺癌试验
- New York City, NY136 项研究
- Houston, TX126 项研究
- Boston, MA112 项研究
- Nashville, TN81 项研究
- Los Angeles, CA73 项研究
- Edison, NJ68 项研究
- St. Louis, MO64 项研究
- Queens, NY64 项研究
- Durham, NC64 项研究
- Chicago, IL59 项研究
- Philadelphia, PA56 项研究
- Dallas, TX55 项研究
Fort Worth的其他研究
- 非小细胞肺癌18 项研究
- 卵巢癌17 项研究
- 子宫内膜癌12 项研究
- 癌症（所有类型）9 项研究
- 前列腺癌9 项研究
- 三阴性乳腺癌7 项研究
- 黄斑变性7 项研究
- 溃疡性结肠炎7 项研究
- 肾癌（肾细胞癌）7 项研究
- 心力衰竭7 项研究
- 转移性癌症7 项研究
- 结直肠癌7 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。